Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.25 3.25% 7.95 2,206,816 10:44:33
Bid Price Offer Price High Price Low Price Open Price
7.90 8.00 8.05 7.80 7.95
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.17 -2.10 22
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:32 O 149,000 7.95 GBX

Evgen Pharma (EVG) Latest News (4)

More Evgen Pharma News
Evgen Pharma Investors    Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-15 16:07:327.95149,00011,845.50O
2021-06-15 15:17:427.9062048.98O
2021-06-15 14:46:317.906,177487.98O
2021-06-15 14:37:047.9725,0001,992.50O
2021-06-15 14:24:487.9038,0503,005.95O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 7.70p.
Evgen Pharma Plc has a 4 week average price of 7.20p and a 12 week average price of 7.20p.
The 1 year high share price is 15.75p while the 1 year low share price is currently 7.20p.
There are currently 274,888,117 shares in issue and the average daily traded volume is 2,975,496 shares. The market capitalisation of Evgen Pharma Plc is £21,853,605.30.
moneymunch: Evgen Pharma plc ("Evgen" or the "Company") Progress on metastatic breast cancer programme Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces new preclinical data which shows SFX-01 may be of benefit to metastatic breast cancer ("mBC") patients who have become resistant to CDK4/6 inhibitors. Since the STEM open-label Phase II trial of SFX-01 in mBC trial concluded, CDK4/6 inhibitors have become standard of care as the first line mBC treatment for the large group of patients who are estrogen receptor positive (ER+ve). These drugs provide an extended period of progression-free survival, but invariably patients' tumours become resistant to them. Options for such patients are limited, especially since drugs used in this setting are poorly tolerated. Accordingly, Evgen's collaborators at the Manchester Breast Centre, the University of Manchester, are conducting further in vitro preclinical work to assess the impact of SFX-01 in CDK4/6 resistance models. An increasing body of in vitro data from there shows that in these models SFX-01 may suppress tumour growth and metastasis in patients who have become resistant to CDK4/6 inhibitors. In particular, SFX-01 reduces the viability and mammosphere colony formation ability of palbociclib-resistant cells in vitro. Palbociclib is the leading CDK4/6 inhibitor. Marketed by Pfizer, it had sales of circa $5bn in 2019. Mammospheres are colonies of primary tumour cells which represent a disease-relevant model to study drug effectiveness. Should these data be reinforced with in vivo work, the Company will pursue a Phase II placebo-controlled study a in second line ER+ve mBC treatment of patients who have failed on CDK4/6 inhibitors. Such a trial could commence in 2022. The Company's previous open-label STEM trial in patients who had not received CDK4/6 inhibitors demonstrated: -- Evidence of anti-cancer activity via objective responses (tumour shrinkage) -- 24% of patients showed a durable clinical benefit for at least six months, despite the late stage of disease and patients' established resistance to hormone therapy. Of these, five patients were still receiving SFX-01 at 12 months and one patient remained on SFX-01treatment for 18 months -- A mild and favourable side effect profile for an anti-cancer drug Dr Huw Jones, CEO of Evgen, commented: "It is exciting that the preliminary data set generated by our colleagues at the Manchester Breast Centre suggests SFX-01 may have a valuable role in the treatment of patients who have developed CDK4/6 resistance patients. We will soon be proceeding with the in vivo work and we are working up the design of the next trial."
moneymunch: RNS Number : 7157B Evgen Pharma PLC 14 June 2021 14 June 2021 Evgen Pharma plc ("Evgen" or the "Company") Progress with Glioma/Glioblastoma programme Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma ("GBM"). Glioma is the most common form of brain tumour affecting around 5 per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour representing 45% of all cases and has a poor prognosis with median survival of around 14 months. Together with neuroblastoma, GBMs now account for more deaths in the under 40s than any other tumour. Previously the Company reported that these data generated by Dr Claudio Festuccia at University L'Aquila showed that with in vivo pre-clinical subcutaneous and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model), SFX-01 produced tumour shrinkage and significantly extended survival times. SFX-01 was also found to potentiate (i.e. substantially increase) the therapeutic effect of radiotherapy in these models. Evgen now report that the in vitro these data from these experiments have been reproduced with very similar results at the University of Auckland using cells generated from freshly extracted patient GBM tissue, rather than the standard GBM cell lines established many decades previously. Further in vivo work has commenced at a contract research organisation to build upon the subcutaneous GBM tumour model experiments conducted by Dr Festuccia. Plans for a Phase II GBM clinical trial with an adaptive design are progressing with a scheduled start in the first half of 2022. In tandem work has started with regulatory advisers on preparation of an Investigational New Drug application for submission to the US Food and Drug Administration in Q4/2021. The therapeutic options for GBM are limited to surgery, radiotherapy and the one drug widely available, temozolomide. There is a clear unmet need for more treatments for use in conjunction with the current standard of care. Dr Huw Jones, Evgen CEO, commented: "Building on this data set generated by Dr Festuccia is a key step in the pathway to commencement of a clinical trial, and we are delighted that the work done at Auckland University has produced such consistent positive results. We are excited by this compelling new data set in a type of cancer which has severely limited therapeutic options for the patient and thank Professor Bruce Baguley and Dr Euphemia Leung for their advice and insightful experiments. We have started the planning for the Phase II trial and are pleased to report the GBM programme is proceeding exactly to plan."
moneymunch: That's his idea of balance, repetition of the same post to be disruptive because he he has no control unlike his Guild member only threads and the reason he had the old EVG thread closed down by his lab rat assistant, and while being ignored proclaims that a debate with me is pointless and will filter me .....ha ha ha ha....i wonder why he doesn't spend more time on the other thread???? Anyways to provide balance to the European Respiratory Society living guidelines, they did provide the following in reference to SNG001, this was published befor SNG's recent phase 2 results that were decidely amibiguous because both cohort groups were from fit and healthy patients only displaying mild symptoms, that saw the share price crash from c£1.35 to below £1 after RNS phase 2 data release, which obvioulsy suggested the market wasn't impressed, until the share price recovered to c£1.75, a staggering increase of c£150m on their market cap which now sits c£320m , and the reason for the recovery was on the release of encouraging in vitro studies, yep that's right, in vitro studies, and good for them, but in vitro studies not good enough for EVG according to his biased logic....ho ho ho ho....Anyways , good luck to all holders of SNG and good look to all holders of EVG.....positive efficacy data on SFX-01 for Covid/ARDS will be transformational for all concerned and no doubt add substantial value to EVG's current bargain £24m market cap....Exciting times with a raft of newsflow from the rest of the pipeline.....also expected soon.;-) .......................... Future research: A recent trial published after the systematic review was completed demonstrated a significant benefit of inhaled interferon β-1a in 101 patients conducted in the UK [103]. While small trials should be treated with caution, this suggests the possibility that inhaled delivery has a different effect to systemic delivery of interferon. Further studies to investigate the efficacy of inhaled interferon beta are justified. hTtps://
moneymunch: 0  0 0 I wonder if the planned IND for SFX-01 in the US is related to Prof Thu Le's ongoing work and evaluation of SFX-01 for CKD at University of Rochester, New that would be big news imho....Gla ;-) February 2020 Professor Le and colleagues have previously published research showing an association between CKD patients with the GSTM1 null allele and more rapid CKD progression, and also that consumption of cruciferous vegetables (a source of sulforaphane) is associated with lower risks of kidney failure, with stronger effects in those having the GSTM1 null allele. On this basis, Professor Le approached Evgen, the developer of SFX-01, a stable form of sulforaphane that has demonstrated excellent safety and tolerability in previous clinical trials. Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing." htTps:// .................... January 2021 Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease January 2021 Nutrients 13(1):266 DOI: 10.3390/nu13010266 Authors: Scott Liebman University of Rochester Thu H Le University of Rochester Medical Center Abstract and Figures The mainstay of therapy for chronic kidney disease is control of blood pressure and proteinuria through the use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) that were introduced more than 20 years ago. Yet, many chronic kidney disease (CKD) patients still progress to end-stage kidney disease√Ę€”the ultimate in failed prevention. While increased oxidative stress is a major molecular underpinning of CKD progression, no treatment modality specifically targeting oxidative stress has been established clinically. Here, we review the influence of oxidative stress in CKD, and discuss regarding the role of the Nrf2 pathway in kidney disease from studies using genetic and pharmacologic approaches in animal models and clinical trials. We will then focus on the promising therapeutic potential of sulforaphane, an isothiocyanate derived from cruciferous vegetables that has garnered significant attention over the past decade for its potent Nrf2-activating effect, and implications for precision medicine. hTtps:// ........................... January 2020 University of Rochester Thu H Le University of Rochester Medical Center GSTM1 Deletion Exaggerates Kidney Injury in Experimental Mouse Models and Confers the Protective Effect of Cruciferous Vegetables in Mice and Humans Significance Statement GSTM1 encodes a member of a superfamily of antioxidant enzymes, and a highly prevalent GSTM1 deletion variant is associated with kidney disease progression in two human study cohorts. In this study, the authors demonstrate that Gstm1 knockout mice exhibit increased oxidative stress, kidney injury, and inflammation in models of CKD and hypertension, and that Gstm1 loss in the parenchyma but not in bone marrow–derived cells drives renal inflammation. Importantly, consumption of broccoli powder or cruciferous vegetables was protective against kidney disease only in Gstm1 knockout mice, and was observed mainly in the human participants in the Atherosclerosis Risk in Communities Study who were homozygous for GSTM1 deletion. These findings suggest that targeting antioxidant therapy specifically in individuals carrying the GSTM1 deletion variant may be effective in delaying kidney disease progression. hTtps://
moneymunch: RNS Number : 4916W Evgen Pharma PLC 26 April 2021 Evgen Pharma Plc ("Evgen" or "the Company") Appointment of Chief Medical Officer Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome, announces that Glen Clack, MD, FFPM will be joining the Company as Chief Medical Officer effective from 1 May 2021. Dr Clack has over 30 years' experience in oncology and translational medicine, and held various roles within AstraZeneca for almost 20 years. Dr Clack has specialised in early phase oncology clinical development with an emphasis on a number of important cancers and has a wealth of experience in conducting and managing clinical trials. He has successfully provided strategic and operational leadership from Phase I through to regulatory submissions and commercialisation. He has been a lead member of study, clinical development and project teams on multiple trials. Glen is an Honorary Professor of Translational Medicine at the University of Sheffield and an MSc Module Tutor and Honorary Lecturer in Translational Science at the University of Manchester. He has an MB BS from the Royal Free Hospital School of Medicine in London, is a Fellow of the Faculty of Pharmaceutical Medicine at the University of Wales and holds an MD from the University of Sheffield. Dr Huw Jones CEO of Evgen commented: "We are delighted to have someone of Glen's experience and knowledge join our team. As we progress further with our clinical programmes, Glen's depth of understanding in the fields where we are active will be invaluable. Glen will also be a key member of the team involved in leveraging our relationships with our many partners. His unique skillset has seen him take responsibility for a number of large, complex projects and he has published over 50 academic papers on various cancers."
moneymunch: RNS Number : 5753U Evgen Pharma PLC 07 April 2021 Evgen Pharma Plc ("Evgen" or "the Company") Publication on sulforaphane in COVID-19 Recent pre-print publication shows in vitro and in vivo antiviral activity of sulforaphane against the virus responsible for COVID-19 Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome notes a recent pre-print publication from Johns Hopkins University, USA1. The publication demonstrates that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by several variants of the SARS-CoV-2 virus and another coronavirus. The paper goes on to demonstrate that the inhibition of SARS-CoV-2 cytotoxicity by sulforaphane occurs both when cells are pre-treated with sulforaphane and when sulforaphane is administered 24 hours after viral inoculation. The work also shows that sulforaphane acts synergistically with the antiviral drug remdesivir. The authors further established that the effects of sulforaphane, administered orally, were observed in vivo in a mouse model infected with the SARS-CoV-2 virus where reduction in both viral load and lung pathology were observed. The data have been published before peer review given the urgency of the current pandemic. Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex. Dr Huw Jones CEO of Evgen commented: "We are pleased to note these findings from Johns Hopkins University. If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study. We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021."
moneymunch: RNS Number : 9197S Evgen Pharma PLC 22 March 2021 Evgen Pharma Plc ("Evgen" or "the Company") Appointment of Chief Business Officer Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome, announces that Helen Kuhlman PhD will be joining the Company as Chief Business Officer effective from 1 April 2021. Dr Kuhlman has over 20 years' experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies. She joins Evgen from the Development Bank of Wales where she was responsible for equity investment in technology companies and for managing investments in the bank's portfolio companies. Prior to that Helen was Vice-President of Corporate Development at Chronos Therapeutics Ltd and was previously at Innovate UK where she created and delivered the £180m Biomedical Catalyst competitive grant scheme funded by the UK government. Dr Kuhlman holds a PhD in physiology and pharmacology from the University of Leicester, UK. Dr Huw Jones CEO of Evgen commented: "We are delighted to appoint Helen to a key senior role within the Company as we increase our focus on potential partnering activities for SFX-01. Helen will also have a key role within the team in providing a commercial focus on our indication selection, horizon scanning and competitor intelligence activities."
moneymunch: Yep, certainly does, and for any newbies looking in for the first time, Jim Mellon is the Chairman of Juvensescene who signed a licensing agreement with Evgen 15/9/20, and so maybe one of the many possible reasons why Octopus have bought 21.8m shares representing 7.96%......Exciting times....Gla ;-) Details of the Agreement The license is for exclusive rights to exploit certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and the Rest of the World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales. Evgen received an initial payment of $250k on signing of the Agreement. Barry Clare, Executive Chairman of Evgen, said: "This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetisation in an area which is outside our focus of therapeutic development in the Nrf2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health products and brings in-depth experience in this sector. We are delighted to have them as a partner. " Colin Watts, Chief Executive Officer of JuvLife Division, said : "We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Juvenescence has built a reputation as a broad-based healthcare company in the Longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen." hTtps://
moneymunch: 3 March 2021 Evgen Pharma plc ("Evgen Pharma" or "the Company") Result of Open Offer Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, is pleased to announce the results of its Open Offer. On 2 February 2021, Evgen announced its intention to raise gross proceeds of up to £11 million by way of a Placing and Open Offer, all at an issue price of 8 pence per New Ordinary Share. A total of 137,490,676 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 12,490,676 New Ordinary Shares will be issued pursuant to the Open Offer. This brings the gross proceeds of the Fundraising to approximately £11 million before expenses. The Open Offer closed for acceptances at 11.00 a.m. yesterday. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 5,389,931 New Ordinary Shares, representing approximately 43 per cent. of the Open Offer Shares. In addition, the Company has received applications from Qualifying Shareholders under the Excess Application Facility in respect of 14,359,431 New Ordinary Shares, representing a total over-subscription of approximately 58 per cent. of the available Open Offer Shares. Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements. As applications under the Excess Application Facility cannot be satisfied in full, applications for New Ordinary Shares under the Excess Application Facility will be scaled back in accordance with the terms set out in the Circular. General Meeting The Fundraising remains conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held at 10:00 a.m. today (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 4 March 2021 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 18 March 2021). The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.
moneymunch: " Two of the most recent examples are the placings by Evgen Pharma plc, the clinical stage company focussed on the treatment of cancer and inflammation, and Synairgen plc, the respiratory drug discovery and development company, both listed on AIM. These biotechs are suddenly in the enviable position of having to choose between scaling back allocations or only accepting the money on the table from specific investors." ......................... Booming biotech sector allows for choices over investment Out-Law Analysis | 23 Feb 2021 There has been a growing interest in biotech companies since the onset of the Covid-19 pandemic. Over $13 billion was invested worldwide in biotech companies in 2020 alone. As a result of this increased flow of capital into the sector, biotech companies are becoming more selective about the investors with whom they choose to partner, taking a longer term view than might have previously been the case in a sector in which the cash burn rate from R&D is well known. This theme of the discerning biotech was a central focus at the recent LSX World Congress. This annual event brings together life sciences industry executives – from those involved in start-ups to those leading the world's biggest pharmaceutical companies – and the investment community. Investors without any particular insights into the sector are naturally drawn to the human stories behind products, and in the biotech sector there is no shortage of narrative that companies can play on Widening interest in the sector Specialist healthcare investors know that investment in biotechs requires a long-term view, recognising that it can take years of research and substantial capital for companies to develop new products and deliver meaningful returns on their investment. The risk involved in picking the correct companies to invest in, and at the right time, has meant that the sector has been the domain of specialist investors who understand the science. This changed with the onset of the pandemic when a growing number of investors recognised that, with so many biotechs pivoting ongoing trials to test whether existing products in development had application to coronavirus, any good news from those companies could lead to substantial bumps in share prices, often in excess of 100%. The potential size of these returns suddenly outweighed the risk that had previously made non-specialist healthcare investors wary of the sector. Moreover, driven by the turmoil in sectors such as retail, hospitality and airlines, companies in the life sciences sector felt like a relatively safe place for institutions to invest. A McKinsey study highlighted at the LSX World Congress indicated that, while biotechs listed on the public markets did experience a downturn in share prices in spring 2020, that downturn was short-lived, with average share prices rising 39% in Europe, 37% in the US and 106% in China between 1 January 2020 and 19 January 2021. As a result, much of the recent investment interest in the biotech sector has been from non-specialist investors whose attention has been drawn by the sector's resilience to the Covid-19 pandemic. Industry success stories also help to raise the profile of the sector. The rise to international prominence of German biotech BioNTech, following its partnership with Pfizer and development of a Covid-19 vaccine, is an example of the attention the sector is gaining for its innovation and real-life impact. Investors without any particular insights into the sector are also naturally drawn to the human stories behind products, and in the biotech sector there is no shortage of narrative that companies can play on. For instance, with recent advances in the use of data and technology, companies have been able to focus their innovation around a 'patient-centric' approach to medicine, with personalised medicine, including cell and gene therapies, which show such promise in the treatment of rare diseases, coming to prominence. Increasingly, the 'story' behind, or theoretic potential of, a product is more important than the data behind it, particularly for non-specialist healthcare investors. This growing interest in the sector has resulted in many of the equity fundraisings conducted by publicly traded biotechs being significantly over-subscribed, as more investors have sought to put their faith in biotech stocks. Two of the most recent examples are the placings by Evgen Pharma plc, the clinical stage company focussed on the treatment of cancer and inflammation, and Synairgen plc, the respiratory drug discovery and development company, both listed on AIM. These biotechs are suddenly in the enviable position of having to choose between scaling back allocations or only accepting the money on the table from specific investors. In addition, the increased flow of cash into the sector is prompting competition between investors about the timing of their investment, with an increasing number prepared to invest earlier in the life cycle of a biotech, often at the 'Series A' funding round. Certain funds that traditionally have been focussed on public markets are re-assessing this focus and looking more closely at early stage biotechs. Marshall Wace and Third Point are two big hedge funds that are currently raising money – $400m and $300m, respectively – to invest in privately held healthcare companies that are between six months and two years out from IPO, with a view to holding on to those companies after they list. While the recent returns on many investments in listed biotechs is impressive, some investors are recognising that even they can be dwarfed if they give their backing to the right company early enough in its development. Those investors know that the best value will come from investing early in a company at cheaper valuations, with the rewards coming if that company has a product approved. The risk/reward analysis has been tipped in favour of reward by the evident strength of biotechs over the last 12 months. hTtps://
Evgen Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210616 02:20:51